Aetna (AET) Still Weighing Whether to Cover Sarepta's (SRPT) Exondys 51 - Bloomberg
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- AMC Entertainment (AMC) Enters $250M ATM Agreement
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- Home Depot (HD) to Acquire SRS Distribution for $18.25B EV
Sarepta (SRPT) PT Raised to $72 at Wedbush Ahead of US Launch of Exondys 51
October 10, 2016 6:52 AM EDTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $72.00 (from $66.00) ahead of the US Launch of Exondys 51.
Behanna commented, "With the first patient dosed with commercial Exondys 51 this week, we have built out our model to look at US potential penetration into each segment of boys amenable to therapy... More
Anthem (ANTM) Dragging Feet on Sarepta's (SRPT) Exondys 51 is Likely Negotiating Tactic - Oppenheimer
October 7, 2016 3:14 PM EDTOppenheimer affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $76 as Anthem said EXONDYS 51 wasn't medically necessary earlier today, putting pressure on SRPT shares.
The firm commented: Anthem's medical policy took the position that eteplirsen (EXONDYS 51) is "investigational and not... More
Humana (HUM) says still weighing whether or not to cover Sarepta's Exondys 51 - Bloomberg
October 7, 2016 2:52 PM EDTHumana (NYSE: HUM) says still weighing whether or not to cover Sarepta's Exondys 51 - Bloomberg
... MoreUnitedHealth Group (UNH) says planning to cover Sarepta's (SRPT) Exondys 51 - Reuters.
October 7, 2016 2:29 PM EDTUnitedHealth Group (NYSE: UNH) says planning to cover Sarepta Therapeutics (Nasdaq: SRPT) Exondys 51, according to Reuters headlines.
Those covering Exondys 51 also includes Cigna (NYSE: CI), while Humana (NYSE:... More
Sarepta Therapeutics (SRPT) Shares Make Strong Move Off Session Lows
October 7, 2016 2:26 PM EDTSarepta Therapeutics (NASDAQ: SRPT) shares are seeing a slight pop higher. Baird was out in defense of the stock this afternoon.
... MoreBaird Says No Change to Sarepta (SRPT) Outlook Amid Anthem Slight
October 7, 2016 1:06 PM EDTBaird analyst Brian Skorney said their is no change to his outlook on Sarepta Therapeutic (NASDAQ: SRPT) amid news Anthem, the nation's second-largest insurer by number of covered lives, issued a coverage policy this morning categorizing Exondys 51 as "not medically necessary."... More
Sarepta Therapeutics (SRPT) Falls as Anthem says Exondys 51 Not Medically Necessary
October 7, 2016 10:39 AM EDTSarepta Therapeutics (NASDAQ: SRPT) ticks lower after Anthem says Exondys 51 not medically necessary. Shares are down 3.2%.
Anthem's position statement:
"The use of eteplirsen is considered investigational and not medically necessary for all indications, including but not limited to the treatment of Duchenne muscular dystrophy."
... More